Oppenheimer trims Walmart rating ahead of Aug. 20 earnings, arguing pharmacy drag is outweighing the upside

Walmart is back in focus with the approach of its next earnings release, after Oppenheimer moved the retailer’s stock rating to Perform from Outperform ahead of its Aug. 20 results.

In its note highlighted by Yahoo Finance, Oppenheimer framed the move around concerns that pharmacy-related issues could weigh on near-term performance. The firm characterized these pharmacy headwinds as a key factor in its shift, suggesting that the market’s expectations may be more optimistic than the operating reality implied by its outlook.

The downgrade also reflected what Oppenheimer views as a valuation that is already “full.” In other words, the firm argued that the stock’s current price leaves less room for upside surprises from operations, even if Walmart continues executing on its broader retail strategy.

Yahoo Finance also tied the story to the question of whether a more bullish valuation gap call is still valid. The article referenced a “28% undervalued” perspective, essentially asking whether that upside view can hold up if pharmacy is indeed a bigger constraint than previously assumed.

For Walmart, the significance of an analyst focus on pharmacy is practical. Pharmacy can be a meaningful contributor to customer traffic and margin mix, and any slowdown or cost pressure can influence how investors think about earnings quality and the timing of improvement. With investors looking toward the Aug. 20 report, pharmacy becomes a natural lens for questions about both revenue resilience and profitability.

More broadly, retail stock moves ahead of earnings often hinge on whether companies can offset specific pressure points with strength elsewhere. In Walmart’s case, the debate implied by the downgrade is whether pharmacy headwinds are likely to be temporary and absorbed into operating progress, or persistent enough to affect the earnings trajectory that investors have priced in.

The market will likely watch not only whether Walmart meets consensus expectations, but also what management says about pharmacy trends going into the second half of the year. However, the post highlighted by Yahoo Finance did not provide detailed operating metrics, guidance figures, or any pharmacy-specific quantitative targets, so the underlying assumptions behind the “full valuation” argument remain a matter of interpretation until the company reports.